• Depot
  • Watchlist
  • Glocke
  • Handeln

    • AstraZeneca plc ADR News

    75,17 $ +0,19% +0,14 $
    In : 70,299 € | 26.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 886715
    ISIN: US0463531089
    US-Symbol: AZN
    Typ: Aktie

    AstraZeneca plc ADR News

    25.04.24 - PR Newswire
    AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
    26.02.24 - PR Newswire
    Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign
    Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign Canada NewsWire
    07.02.24 - PR Newswire
    SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
    SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain PR Newswire
    07.02.24 - PR Newswire
    SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
    SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain PR Newswire
    08.01.24 - PR Newswire
    Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
    Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire
    02.01.24 - PR Newswire
    Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
    Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-​Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca PR Newswire
    02.01.24 - PR Newswire
    Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
    Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-​Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca PR Newswire
    19.12.23 - PR Newswire
    Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
    Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire
    30.11.23 - PR Newswire
    Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
    Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-​Oncology Drug Combinations with CIVO® Technology PR Newswire
    10.11.23 - ARIVA.DE Redaktion
    Nasdaq 100 zur Stunde 2,02 Prozent mehr (15.495 Pkt.)
    Die Aktie von KLA-​Tencor ist derzeit der größte Gewinner im Nasdaq 100-Index. Der Index steigt stark um 2,02 Prozent.
    10.11.23 - ARIVA.DE Redaktion
    0,68 Prozent Plus: Nasdaq 100 legt etwas zu (15.290 Pkt.)
    Für den Nasdaq 100-Index verlief der bisherige Aktienhandel heute positiv. Das Börsenbarometer steigt kräftig um 0,68 Prozent.
    20.10.23 - PR Newswire
    Thinking about trading options or stock in NVIDIA, CVS Health, PayPal Holdings, AstraZeneca, or BP?
    Thinking about trading options or stock in NVIDIA, CVS Health, PayPal Holdings, AstraZeneca, or BP? PR Newswire
    18.10.23 - ARIVA.DE Redaktion
    1,28 Prozent Minus: Nasdaq 100 tendiert leichter (14.928 Pkt.)
    Für den Nasdaq 100-Index brachte der bisherige Aktienhandel heute leichte Verluste. Das Börsenbarometer rutscht um 1,28 Prozent ab.
    18.10.23 - ARIVA.DE Redaktion
    Nasdaq 100 gibt leicht nach: 154 Punkte verloren (14.968 Pkt.)
    Für den Nasdaq 100-Index brachte der bisherige Aktienhandel heute leichte Verluste. Das Börsenbarometer sinkt leicht um 1,02 Prozent.
    18.10.23 - ARIVA.DE Redaktion
    Nasdaq 100 heute kaum bewegt (15.090 Pkt.)
    Kurs­verluste und Kursgewinn halten sich beim Nasdaq 100 gegenwärtig in etwa die Waage. Derzeit liegt das Kursbarometer mit 0,21 Prozent ganz leicht im Minus.
    18.10.23 - PR Newswire
    SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
    SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care PR ...
    18.10.23 - PR Newswire
    SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
    SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care PR ...
    13.10.23 - PR Newswire
    New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
    New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review PR Newswire
    13.10.23 - PR Newswire
    New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
    New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review PR Newswire
    12.10.23 - PR Newswire
    Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
    Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »